Cancer

April 2, 2026

AACR 2019: Tarloxotinib promising against NRG1-fusion cancers

Credit: University of Colorado Cancer Center A study by University of Colorado Cancer Center and Rain Therapeutics, Inc. presented at...

AACR: Adavosertib speeds cancer cells into the wall of mitotic catastrophe

Credit: University of Colorado Cancer Center A cancer cell is like a racecar, speeding through the process of cellular replication....

Global microbial signatures for colorectal cancer established

Colorectal cancer is characterised by consistent changes in our gut bacteria across continents, cultures, and dietsCredit: EMBL in collaboration with...

Blocking platelets: A possible option to prevent fatty liver disease and liver cancer

Blood platelets which interact with liver cells and immune cells play a major role in the development of fatty liver...

Colorado drug takes aim at cancer metastasis

Credit: University of Colorado Cancer Center Many cancers are relatively harmless at their site of origin, and it is only...

Estrogen byproducts linked to survival in breast cancer patients

Researchers from the University of North Carolina Lineberger Comprehensive Cancer Center found preliminary evidence that measuring byproducts of the hormone...

HDAC inhibition may combat resistance to anti-PD-1 therapy in patients with melanoma

ATLANTA -- A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab (Keytruda) showed clinical...

Researchers discover how tumor-killing immune cells attack lymphomas in living mice

Credit: Cazaux et al., 2019 In a study that will be published April 1 in the Journal of Experimental Medicine,...

Gilteritinib improved survival for patients with acute myeloid leukemia

ATLANTA -- Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid leukemia...

Cancer preventive vaccine showed promising results in preclinical model of Lynch syndrome

ATLANTA -- Vaccination with as few as four tumor antigens generated antigen-specific responses, reduced intestinal tumors, and improved survival in...

Umbralisib shows early promise for patients with marginal zone lymphoma

ATLANTA -- The investigational therapeutic umbralisib, which targets the molecule PI3K-delta, was well tolerated and highly active in patients with...

Data from two KEYNOTE trials show pembrolizumab benefited patients with advanced SCLC

ATLANTA -- The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated, advanced...

Targeted drug for leukemia tested at Penn Medicine helps patients live longer

Data presented at AACR Annual Meeting on recently approved drug that targets common mutation in AML ATLANTA - An inhibitor...

CD40 combination therapy can shrink pancreatic tumors

Study results to be presented during a plenary session at AACR Annual Meeting ATLANTA - A new combination of immunotherapy...

Excess body weight before 50 is associated with higher risk of dying from pancreatic cancer

ATLANTA --Excess weight before age 50 may be more strongly associated with pancreatic cancer mortality risk than excess weight at...

Pancreatic Cancer Collective funds two AI teams to identify high-risk populations

Computational tools seek to identify pancreatic cancer earlier, provide more opportunities for timely, effective treatmentsCredit: Pancreatic Cancer Collective (ATLANTA -...

Immunotherapy combination effective for patients with rare neuroendocrine cancer

Credit: Hope Foundation for Cancer Research A combination of two common immunotherapy drugs shrinks rare, aggressive neuroendocrine tumors, according to...

Adding savolitinib to osimertinib beneficial for certain pretreated lung cancer patients

ATLANTA -- Adding the investigational MET inhibitor savolitinib to the EGFR inhibitor osimertinib (Tagrisso) yielded clinical responses in patients who...

Immune checkpoint inhibitor combo efficacious for patients with neuroendocrine carcinoma

ATLANTA -- A combination of the anti-CTLA-4 immunotherapeutic ipilimumab (Yervoy) and the anti-PD-1 immunotherapeutic nivolumab (Opdivo) showed clinical benefit among...

HER2-targeted CAR T-cell therapy shows promising antitumor activity in patients with sarcoma